{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:21:34Z","timestamp":1787937694721,"version":"build-2784847793"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T cell-based immunotherapies have improved cancer treatment, however their efficacy is frequently limited by tumor-intrinsic resistance mechanisms and by the immune suppressive tumor microenvironment, counteracting tumor specific immune responses through impaired antigen presentation and the accumulation of M2-like tumor-associated macrophages. MicroRNAs have emerged as regulators of tumor cell \u2013 immune cell interactions, yet the miRNAs\u2019 capacity to coordinate anti-tumor effects across different cell types is poorly understood. This study aimed to investigate whether miR-155-5p and miR-3535 represent regulators capable of driving coordinated functional reprogramming of both, tumor cells and macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Human tumor cell lines of various cancer entities were transfected with miR-155-5p or miR-3535 and the resulting effects on immune checkpoint molecule expression and tumor cell proliferation were assessed on transcriptional and functional level. Similarly, human PBMC-derived M2 polarized macrophages were transfected with the same microRNAs, followed by analysis of the cytokine secretion patterns and by transcriptomic profiling to evaluate the macrophage polarization states and the immune-regulatory pathways involved. Transcription factor activity and pathway enrichment analyses were performed to identify the regulatory mechanisms affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both miR-155-5p and miR-3535 reduced expression of the immune checkpoint molecule CD73 (NT5E) in tumor cells, while miR-155-5p additionally suppressed PD-L1 (CD274) expression. At the same time, both microRNAs reprogrammed M2-like macrophages toward a pro-inflammatory M1-like phenotype, characterized by increased TNF\u03b1 and CXCL10 secretion and the induction of M1-associated gene expression. Transcriptomic analysis revealed activation of STAT1\/IRF-driven inflammatory pathways and a reduced activity of ZNF703, representing a transcriptional hub associated with M2 macrophage infiltration and poor prognosis. Both microRNAs increased TAP1 expression, suggesting enhanced antigen-processing capacity. Furthermore, miR-155-5p and miR-3535 exerted anti-proliferative effects across cell lines of various tumor entities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>miR-155-5p and miR-3535 modulate tumor-intrinsic immune checkpoint expression and functional macrophage polarization in a coordinated way, linking tumor cell plasticity to neutralization of the immunosuppressive tumor environment. These findings highlight the potential of coordinated microRNA-mediated regulation via different cell types to overcome immune resistance mechanisms in tumors and support further investigation of microRNA-based strategies in cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05146-7","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:04:07Z","timestamp":1787828647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-8518","authenticated-orcid":false,"given":"Theresa","family":"Korda\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Katrin","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijan","family":"Czygan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Vieira","family":"Codeco Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Wartusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincencia Stefanie","family":"Muliawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Osen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan B.","family":"Eichm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"3","key":"5146_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/vaccines10030457","volume":"10","author":"S Quinn","year":"2022","unstructured":"Quinn S, Lenart N, Dronzek V, Scurti GM, Hossain NM, Nishimura MI. Genetic Modification of T Cells for the Immunotherapy of Cancer. Vaccines (Basel). 2022;10(3):457. https:\/\/doi.org\/10.3390\/vaccines10030457.","journal-title":"Vaccines (Basel)"},{"key":"5146_CR2","doi-asserted-by":"publisher","first-page":"927265","DOI":"10.3389\/fimmu.2022.927265","volume":"13","author":"EK Moore","year":"2022","unstructured":"Moore EK, Strazza M, Mor A. Combination Approaches to Target PD-1 Signaling in Cancer. Front Immunol. 2022;13:927265. https:\/\/doi.org\/10.3389\/fimmu.2022.927265.","journal-title":"Front Immunol"},{"key":"5146_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00114","volume":"3","author":"E Pons-Tostivint","year":"2019","unstructured":"Pons-Tostivint E, Latouche A, Vaflard P, et al. Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials. JCO Precis Oncol. 2019;3:1\u201310. https:\/\/doi.org\/10.1200\/PO.18.00114.","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"5146_CR4","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"issue":"4","key":"5146_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23(4):238\u201357. https:\/\/doi.org\/10.1038\/s41568-022-00547-1.","journal-title":"Nat Rev Cancer"},{"key":"5146_CR6","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11:583084. https:\/\/doi.org\/10.3389\/fimmu.2020.583084.","journal-title":"Front Immunol"},{"issue":"3","key":"5146_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/path.1027","volume":"196","author":"L Bingle","year":"2002","unstructured":"Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254\u201365. https:\/\/doi.org\/10.1002\/path.1027.","journal-title":"J Pathol"},{"issue":"1","key":"5146_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","volume":"12","author":"M Li","year":"2022","unstructured":"Li M, He L, Zhu J, Zhang P, Liang S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 2022;12(1):85. https:\/\/doi.org\/10.1186\/s13578-022-00823-5.","journal-title":"Cell Biosci"},{"issue":"5","key":"5146_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014.","journal-title":"Cancer Cell"},{"issue":"24","key":"5146_CR10","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1158\/0008-5472.CAN-16-1456","volume":"76","author":"A Metelli","year":"2016","unstructured":"Metelli A, Wu BX, Fugle CW, et al. Surface Expression of TGF\u03b2 Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. Cancer Res. 2016;76(24):7106\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1456.","journal-title":"Cancer Res"},{"issue":"1","key":"5146_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DVF Tauriello","year":"2022","unstructured":"Tauriello DVF, Sancho E, Batlle E. Overcoming TGF\u03b2-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25\u201344. https:\/\/doi.org\/10.1038\/s41568-021-00413-6.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5146_CR12","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang X, Yang X, Zhang C, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A. 2020;117(12):6640\u201350. https:\/\/doi.org\/10.1073\/pnas.1921445117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5146_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, Xu X, Chitre AS, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8\u2009+\u2009T cell responses. Immunity. 2022;55(3):512\u2013e5269. https:\/\/doi.org\/10.1016\/j.immuni.2022.02.005.","journal-title":"Immunity"},{"issue":"1","key":"5146_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344. https:\/\/doi.org\/10.1111\/imr.12528.","journal-title":"Immunol Rev"},{"issue":"2","key":"5146_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333. https:\/\/doi.org\/10.1016\/j.cell.2009.01.002.","journal-title":"Cell"},{"issue":"4","key":"5146_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3892\/or.2023.8627","volume":"50","author":"C Wang","year":"2023","unstructured":"Wang C, Wang X, Zhang D, et al. The macrophage polarization by miRNAs and its potential role in the treatment of tumor and inflammation (Review). Oncol Rep. 2023;50(4):190. https:\/\/doi.org\/10.3892\/or.2023.8627.","journal-title":"Oncol Rep"},{"key":"5146_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2018.05.015","volume":"431","author":"Q Yang","year":"2018","unstructured":"Yang Q, Cao W, Wang Z, Zhang B, Liu J. Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins. Cancer Lett. 2018;431:73\u201384. https:\/\/doi.org\/10.1016\/j.canlet.2018.05.015.","journal-title":"Cancer Lett"},{"key":"5146_CR18","doi-asserted-by":"publisher","first-page":"982902","DOI":"10.3389\/fimmu.2022.982902","volume":"13","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Shoorei H, Hussen BM, Poornajaf Y, Taheri M, Sharifi G. Interplay between programmed death-ligand 1 and non-coding RNAs. Front Immunol. 2022;13:982902. https:\/\/doi.org\/10.3389\/fimmu.2022.982902.","journal-title":"Front Immunol"},{"key":"5146_CR19","doi-asserted-by":"publisher","first-page":"1199374","DOI":"10.3389\/fimmu.2023.1199374","volume":"14","author":"T Korda\u00df","year":"2023","unstructured":"Korda\u00df T, Chao TY, Osen W, Eichm\u00fcller SB. Novel microRNAs modulating ecto-5\u2019-nucleotidase expression. Front Immunol. 2023;14:1199374. https:\/\/doi.org\/10.3389\/fimmu.2023.1199374.","journal-title":"Front Immunol"},{"key":"5146_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fimmu.2018.00813","volume":"9","author":"T Korda\u00df","year":"2018","unstructured":"Korda\u00df T, Osen W, Eichm\u00fcller SB. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73\/NT5E. Front Immunol. 2018;9:813. https:\/\/doi.org\/10.3389\/fimmu.2018.00813.","journal-title":"Front Immunol"},{"issue":"6","key":"5146_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","volume":"38","author":"C Diener","year":"2022","unstructured":"Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38(6):613\u201326. https:\/\/doi.org\/10.1016\/j.tig.2022.02.006.","journal-title":"Trends Genet"},{"key":"5146_CR22","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3389\/fimmu.2018.02491","volume":"9","author":"N Yang","year":"2018","unstructured":"Yang N, Zhu S, Lv X, Qiao Y, Liu YJ, Chen J. MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment. Front Immunol. 2018;9:2491. https:\/\/doi.org\/10.3389\/fimmu.2018.02491.","journal-title":"Front Immunol"},{"issue":"3","key":"5146_CR23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/ijms25031469","volume":"25","author":"AA Seyhan","year":"2024","unstructured":"Seyhan AA. Trials and Tribulations of MicroRNA Therapeutics. Int J Mol Sci. 2024;25(3):1469. https:\/\/doi.org\/10.3390\/ijms25031469.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5146_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00018-017-2656-0","volume":"75","author":"H Seok","year":"2018","unstructured":"Seok H, Lee H, Jang ES, Chi SW. Evaluation and control of miRNA-like off-target repression for RNA interference. Cell Mol Life Sci. 2018;75(5):797\u2013814. https:\/\/doi.org\/10.1007\/s00018-017-2656-0.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"5146_CR25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41587-024-02480-0","volume":"42","author":"What will it take to get miRNA therapies to market?","year":"2024","unstructured":"What will it take to get miRNA therapies to market?. Nat Biotechnol. 2024;42(11):1623\u20134. https:\/\/doi.org\/10.1038\/s41587-024-02480-0.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"5146_CR26","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","volume":"2","author":"S Ugurel","year":"2007","unstructured":"Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE. 2007;2(2):e236. https:\/\/doi.org\/10.1371\/journal.pone.0000236.","journal-title":"PLoS ONE"},{"issue":"2","key":"5146_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.bmc.2006.10.015","volume":"15","author":"S Nagashima","year":"2007","unstructured":"Nagashima S, Yokota M, Nakai E, ichi, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007;15(2):1044\u201355. https:\/\/doi.org\/10.1016\/j.bmc.2006.10.015.","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"5146_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1124\/jpet.110.170555","volume":"335","author":"DM Clausen","year":"2010","unstructured":"Clausen DM, Guo J, Parise RA, et al. In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc\/Max Dimerization. J Pharmacol Exp Ther. 2010;335(3):715\u201327. https:\/\/doi.org\/10.1124\/jpet.110.170555.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"5146_CR29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","volume":"13","author":"J Schust","year":"2006","unstructured":"Schust J, Sperl B, Hollis A, Mayer TU, Berg T, Stattic. A Small-Molecule Inhibitor of STAT3 Activation and Dimerization. Chem Biol. 2006;13(11):1235\u201342. https:\/\/doi.org\/10.1016\/j.chembiol.2006.09.018.","journal-title":"Chem Biol"},{"issue":"6","key":"5146_CR30","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3892\/ijo.2016.3728","volume":"49","author":"L Lin","year":"2016","unstructured":"Lin L, Jou D, Wang Y, et al. STAT3 as a potential therapeutic target in ALDH\u2009+\u2009and CD44+\/CD24\u2009+\u2009stem cell-like pancreatic cancer cells. Int J Oncol. 2016;49(6):2265\u201374. https:\/\/doi.org\/10.3892\/ijo.2016.3728.","journal-title":"Int J Oncol"},{"issue":"7","key":"5146_CR31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","volume":"6","author":"H Xiao","year":"2020","unstructured":"Xiao H, Guo Y, Li B, et al. M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKK\u03b2 siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects. ACS Cent Sci. 2020;6(7):1208\u201322. https:\/\/doi.org\/10.1021\/acscentsci.9b01235.","journal-title":"ACS Cent Sci"},{"issue":"12","key":"5146_CR32","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.bmc.2017.03.036","volume":"25","author":"S Gao","year":"2017","unstructured":"Gao S, Zang J, Gao Q, et al. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. Bioorg Med Chem. 2017;25(12):2981\u201394. https:\/\/doi.org\/10.1016\/j.bmc.2017.03.036.","journal-title":"Bioorg Med Chem"},{"key":"5146_CR33","doi-asserted-by":"publisher","first-page":"112112","DOI":"10.1016\/j.biopha.2021.112112","volume":"142","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Abak A, Tavakkoli Avval S, Shoorei H, Taheri M, Samadian M. The impact of non-coding RNAs on macrophage polarization. Biomed Pharmacother. 2021;142:112112. https:\/\/doi.org\/10.1016\/j.biopha.2021.112112.","journal-title":"Biomed Pharmacother"},{"key":"5146_CR34","doi-asserted-by":"publisher","first-page":"1147710","DOI":"10.3389\/fimmu.2023.1147710","volume":"14","author":"W Yu","year":"2023","unstructured":"Yu W, Wang S, Wang Y, et al. MicroRNA: role in macrophage polarization and the pathogenesis of the liver fibrosis. Front Immunol. 2023;14:1147710. https:\/\/doi.org\/10.3389\/fimmu.2023.1147710.","journal-title":"Front Immunol"},{"key":"5146_CR35","doi-asserted-by":"publisher","unstructured":"Mu W, Zhang W. Bioinformatic Resources of microRNA Sequences, Gene Targets, and Genetic Variation. Front Gene. 2012;3. https:\/\/doi.org\/10.3389\/fgene.2012.00031.","DOI":"10.3389\/fgene.2012.00031"},{"issue":"D1","key":"5146_CR36","doi-asserted-by":"publisher","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127\u201331. https:\/\/doi.org\/10.1093\/nar\/gkz757.","journal-title":"Nucleic Acids Res"},{"issue":"Database","key":"5146_CR37","doi-asserted-by":"publisher","first-page":"D105","DOI":"10.1093\/nar\/gkn851","volume":"37","author":"F Xiao","year":"2009","unstructured":"Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37(Database):D105\u201310. https:\/\/doi.org\/10.1093\/nar\/gkn851.","journal-title":"Nucleic Acids Res"},{"issue":"Database","key":"5146_CR38","doi-asserted-by":"publisher","first-page":"D159","DOI":"10.1093\/nar\/gkm829","volume":"36","author":"S Nam","year":"2007","unstructured":"Nam S, Kim B, Shin S, Lee S. miRGator: an integrated system for functional annotation of microRNAs. Nucleic Acids Res. 2007;36(Database):D159\u201364. https:\/\/doi.org\/10.1093\/nar\/gkm829.","journal-title":"Nucleic Acids Res"},{"issue":"Database","key":"5146_CR39","doi-asserted-by":"publisher","first-page":"D165","DOI":"10.1093\/nar\/gkm1012","volume":"36","author":"SD Hsu","year":"2007","unstructured":"Hsu SD, Chu CH, Tsou AP, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2007;36(Database):D165\u20139. https:\/\/doi.org\/10.1093\/nar\/gkm1012.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"5146_CR40","doi-asserted-by":"publisher","first-page":"W474","DOI":"10.1093\/nar\/gkv457","volume":"43","author":"M \u0160ulc","year":"2015","unstructured":"\u0160ulc M, Mar\u00edn RM, Robins HS, Van\u00ed\u010dek J. PACCMIT\/PACCMIT-CDS: identifying microRNA targets in 3\u2032 UTRs and coding sequences. Nucleic Acids Res. 2015;43(W1):W474\u20139. https:\/\/doi.org\/10.1093\/nar\/gkv457.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5146_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ng1536","volume":"37","author":"A Krek","year":"2005","unstructured":"Krek A, Gr\u00fcn D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495\u2013500. https:\/\/doi.org\/10.1038\/ng1536.","journal-title":"Nat Genet"},{"issue":"10","key":"5146_CR42","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/ng2135","volume":"39","author":"M Kertesz","year":"2007","unstructured":"Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278\u201384. https:\/\/doi.org\/10.1038\/ng2135.","journal-title":"Nat Genet"},{"key":"5146_CR43","doi-asserted-by":"publisher","first-page":"e05005","DOI":"10.7554\/eLife.05005","volume":"4","author":"V Agarwal","year":"2015","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005. https:\/\/doi.org\/10.7554\/eLife.05005.","journal-title":"eLife"},{"issue":"8","key":"5146_CR44","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/gb-2010-11-8-r90","volume":"11","author":"D Betel","year":"2010","unstructured":"Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010;11(8):R90. https:\/\/doi.org\/10.1186\/gb-2010-11-8-r90.","journal-title":"Genome Biol"},{"issue":"3","key":"5146_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019;76(3):359\u201370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030.","journal-title":"Mol Cell"},{"key":"5146_CR46","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.bbrep.2022.101369","volume":"32","author":"K Sri-ngern-ngam","year":"2022","unstructured":"Sri-ngern-ngam K, Keawvilai P, Pisitkun T, Palaga T. Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes. Biochem Biophys Rep. 2022;32:101369. https:\/\/doi.org\/10.1016\/j.bbrep.2022.101369.","journal-title":"Biochem Biophys Rep"},{"issue":"17","key":"5146_CR47","doi-asserted-by":"publisher","first-page":"i401","DOI":"10.1093\/bioinformatics\/btu446","volume":"30","author":"T Schacht","year":"2014","unstructured":"Schacht T, Oswald M, Eils R, Eichm\u00fcller SB, K\u00f6nig R. Estimating the activity of transcription factors by the effect on their target genes. Bioinformatics. 2014;30(17):i401\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btu446.","journal-title":"Bioinformatics"},{"issue":"1","key":"5146_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s10020-025-01325-z","volume":"31","author":"C Hu","year":"2025","unstructured":"Hu C, Hu T, Wen J, Jia Z. Human papillomavirus-related syntaxin 11 reprograms tumor-associated macrophages to induce breast cancer cell apoptosis via PI3K\/AKT signaling. Mol Med. 2025;31(1):285. https:\/\/doi.org\/10.1186\/s10020-025-01325-z.","journal-title":"Mol Med"},{"issue":"10","key":"5146_CR49","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12742","volume":"106","author":"N Yoshida","year":"2015","unstructured":"Yoshida N, Tsuzuki S, Karube K, et al. STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas. Cancer Sci. 2015;106(10):1455\u201362. https:\/\/doi.org\/10.1111\/cas.12742.","journal-title":"Cancer Sci"},{"issue":"6","key":"5146_CR50","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/cam4.3678","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Fu W, Chen W, Lin Y, Zhang J, Song C. Correlation of immune infiltration with clinical outcomes in breast cancer patients: The 25-gene prognostic signatures model. Cancer Med. 2021;10(6):2112\u201324. https:\/\/doi.org\/10.1002\/cam4.3678.","journal-title":"Cancer Med"},{"issue":"8","key":"5146_CR51","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-09-4250","volume":"70","author":"S Jiang","year":"2010","unstructured":"Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4250.","journal-title":"Cancer Res"},{"issue":"13","key":"5146_CR52","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","volume":"76","author":"AA Svoronos","year":"2016","unstructured":"Svoronos AA, Engelman DM, Slack FJ. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 2016;76(13):3666\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0359.","journal-title":"Cancer Res"},{"issue":"9","key":"5146_CR53","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.3390\/ijms24097825","volume":"24","author":"T Kalantzakos","year":"2023","unstructured":"Kalantzakos T, Hooper K, Das S, et al. MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells. Int J Mol Sci. 2023;24(9):7825. https:\/\/doi.org\/10.3390\/ijms24097825.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5146_CR54","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3892\/ijmm.2016.2529","volume":"37","author":"Q Zeng","year":"2016","unstructured":"Zeng Q, Tao X, Huang F, et al. Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6\/cyclin D2. Int J Mol Med. 2016;37(5):1274\u201380. https:\/\/doi.org\/10.3892\/ijmm.2016.2529.","journal-title":"Int J Mol Med"},{"issue":"12","key":"5146_CR55","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3390\/biomedicines12122658","volume":"12","author":"E Koumpis","year":"2024","unstructured":"Koumpis E, Georgoulis V, Papathanasiou K, et al. The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma. Biomedicines. 2024;12(12):2658. https:\/\/doi.org\/10.3390\/biomedicines12122658.","journal-title":"Biomedicines"},{"issue":"21","key":"5146_CR56","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.3390\/cancers14215414","volume":"14","author":"K Kalkusova","year":"2022","unstructured":"Kalkusova K, Taborska P, Stakheev D, Smrz D. The Role of miR-155 in Antitumor Immunity. Cancers. 2022;14(21):5414. https:\/\/doi.org\/10.3390\/cancers14215414.","journal-title":"Cancers"},{"key":"5146_CR57","doi-asserted-by":"publisher","unstructured":"Wang J, Yu F, Jia X, et al. Micro RNA -155 deficiency enhances the recruitment and functions of myeloid\u2010derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Intl J Cancer. 2015;136(6). https:\/\/doi.org\/10.1002\/ijc.29151.","DOI":"10.1002\/ijc.29151"},{"issue":"19","key":"5146_CR58","doi-asserted-by":"publisher","first-page":"e157248","DOI":"10.1172\/JCI157248","volume":"132","author":"J Wang","year":"2022","unstructured":"Wang J, Wang Q, Guan Y, et al. Breast cancer cell\u2013derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Invest. 2022;132(19):e157248. https:\/\/doi.org\/10.1172\/JCI157248.","journal-title":"J Clin Invest"},{"issue":"2","key":"5146_CR59","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2012-08-449306","volume":"122","author":"E Zonari","year":"2013","unstructured":"Zonari E, Pucci F, Saini M, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013;122(2):243\u201352. https:\/\/doi.org\/10.1182\/blood-2012-08-449306.","journal-title":"Blood"},{"issue":"4","key":"5146_CR60","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","volume":"124","author":"B Cui","year":"2014","unstructured":"Cui B, Chen L, Zhang S, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546\u201354. https:\/\/doi.org\/10.1182\/blood-2014-03-559690.","journal-title":"Blood"},{"issue":"10","key":"5146_CR61","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1073\/pnas.0500613102","volume":"102","author":"PS Eis","year":"2005","unstructured":"Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627\u201332. https:\/\/doi.org\/10.1073\/pnas.0500613102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5146_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejca.2012.09.031","volume":"49","author":"M Yang","year":"2013","unstructured":"Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013;49(3):604\u201315. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.031.","journal-title":"Eur J Cancer"},{"issue":"8","key":"5146_CR63","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-09-4250","volume":"70","author":"S Jiang","year":"2010","unstructured":"Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4250.","journal-title":"Cancer Res"},{"issue":"6","key":"5146_CR64","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/onc.2012.636","volume":"33","author":"W Kong","year":"2014","unstructured":"Kong W, He L, Richards EJ, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679\u201389. https:\/\/doi.org\/10.1038\/onc.2012.636.","journal-title":"Oncogene"},{"key":"5146_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clineuro.2018.12.005","volume":"176","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Wang X, Liu Z, et al. Prognostic role of microRNA-155 expression in gliomas: A meta-analysis. Clin Neurol Neurosurg. 2019;176:103\u20139. https:\/\/doi.org\/10.1016\/j.clineuro.2018.12.005.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"5146_CR66","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/2211-5463.12853","volume":"10","author":"J Huang","year":"2020","unstructured":"Huang J, Weng Q, Shi Y, et al. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. FEBS Open Bio. 2020;10(6):1065\u201371. https:\/\/doi.org\/10.1002\/2211-5463.12853.","journal-title":"FEBS Open Bio"},{"issue":"50","key":"5146_CR67","doi-asserted-by":"publisher","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","volume":"292","author":"D Yee","year":"2017","unstructured":"Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. MicroRNA-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017;292(50):20683\u201393. https:\/\/doi.org\/10.1074\/jbc.M117.809053.","journal-title":"J Biol Chem"},{"issue":"9","key":"5146_CR68","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41401-023-01079-6","volume":"44","author":"SA Kov\u00e1cs","year":"2023","unstructured":"Kov\u00e1cs SA, Fekete JT, Gy\u0151rffy B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacol Sin. 2023;44(9):1879\u201389. https:\/\/doi.org\/10.1038\/s41401-023-01079-6.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"5146_CR69","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/ctm2.70010","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Lazaridou M, Korda\u00df T, et al. Unconventional microRNA role: Enhancing the human leukocyte antigen class I antigen processing pathway via interacting with a silencer. Clin Translational Med. 2024;14(10):e70010. https:\/\/doi.org\/10.1002\/ctm2.70010.","journal-title":"Clin Translational Med"},{"issue":"5","key":"5146_CR70","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1073\/pnas.0610731104","volume":"104","author":"RM O\u2019Connell","year":"2007","unstructured":"O\u2019Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604\u20139. https:\/\/doi.org\/10.1073\/pnas.0610731104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5146_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jmcb\/mjs044","volume":"4","author":"X Cai","year":"2012","unstructured":"Cai X, Yin Y, Li N, et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol. 2012;4(5):341\u20133. https:\/\/doi.org\/10.1093\/jmcb\/mjs044.","journal-title":"J Mol Cell Biol"},{"issue":"2","key":"5146_CR72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2012-08-449306","volume":"122","author":"E Zonari","year":"2013","unstructured":"Zonari E, Pucci F, Saini M, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013;122(2):243\u201352. https:\/\/doi.org\/10.1182\/blood-2012-08-449306.","journal-title":"Blood"},{"issue":"11","key":"5146_CR73","first-page":"2623","volume":"53","author":"R Beyaert","year":"1993","unstructured":"Beyaert R, Vanhaesebroeck B, Heyninck K, et al. Sensitization of tumor cells to tumor necrosis factor action by the protein kinase inhibitor staurosporine. Cancer Res. 1993;53(11):2623\u201330.","journal-title":"Cancer Res"},{"issue":"4","key":"5146_CR74","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/cgt.2008.86","volume":"16","author":"HJ Mauceri","year":"2009","unstructured":"Mauceri HJ, Beckett MA, Liang H, et al. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009;16(4):373\u201381. https:\/\/doi.org\/10.1038\/cgt.2008.86.","journal-title":"Cancer Gene Ther"},{"key":"5146_CR75","doi-asserted-by":"publisher","unstructured":"Shinn CK, Saddawi-Konefka R, Salanga CL, Schokrpur S, Gutkind JS, Handel TM. Activating the CXCR3\/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinoma. Cancer Biology Preprint posted online April. 2025;28. https:\/\/doi.org\/10.1101\/2025.04.24.650529.","DOI":"10.1101\/2025.04.24.650529"},{"issue":"9","key":"5146_CR76","doi-asserted-by":"publisher","first-page":"e003521","DOI":"10.1136\/jitc-2021-003521","volume":"9","author":"R Reschke","year":"2021","unstructured":"Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021;9(9):e003521. https:\/\/doi.org\/10.1136\/jitc-2021-003521.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"5146_CR77","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/ijms25031860","volume":"25","author":"SK Suleimanov","year":"2024","unstructured":"Suleimanov SK, Efremov YM, Klyucherev TO, et al. Radical-Generating Activity, Phagocytosis, and Mechanical Properties of Four Phenotypes of Human Macrophages. IJMS. 2024;25(3):1860. https:\/\/doi.org\/10.3390\/ijms25031860.","journal-title":"IJMS"},{"issue":"6","key":"5146_CR78","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ Van Elsas","year":"2024","unstructured":"Van Elsas MJ, Middelburg J, Labrie C, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42(6):1032\u2013e105010. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.011.","journal-title":"Cancer Cell"},{"issue":"2","key":"5146_CR79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00438-010-0556-1","volume":"284","author":"K Miyoshi","year":"2010","unstructured":"Miyoshi K, Miyoshi T, Siomi H. Many ways to generate microRNA-like small RNAs: non-canonical pathways for microRNA production. Mol Genet Genomics. 2010;284(2):95\u2013103. https:\/\/doi.org\/10.1007\/s00438-010-0556-1.","journal-title":"Mol Genet Genomics"},{"issue":"17","key":"5146_CR80","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1101\/gad.1953310","volume":"24","author":"MMW Chong","year":"2010","unstructured":"Chong MMW, Zhang G, Cheloufi S, Neubert TA, Hannon GJ, Littman DR. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev. 2010;24(17):1951\u201360. https:\/\/doi.org\/10.1101\/gad.1953310.","journal-title":"Genes Dev"},{"key":"5146_CR81","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402. https:\/\/doi.org\/10.3389\/fendo.2018.00402.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5146_CR82","doi-asserted-by":"publisher","first-page":"726387","DOI":"10.3389\/fgene.2021.726387","volume":"12","author":"B Xu","year":"2021","unstructured":"Xu B, Peng Z, Yan G, et al. Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Patients With Colon Cancer and to Assist in Immunotherapy. Front Genet. 2021;12:726387. https:\/\/doi.org\/10.3389\/fgene.2021.726387.","journal-title":"Front Genet"},{"issue":"7","key":"5146_CR83","doi-asserted-by":"publisher","first-page":"e934","DOI":"10.1002\/ctm2.934","volume":"12","author":"CK Vaxevanis","year":"2022","unstructured":"Vaxevanis CK, Friedrich M, Tretbar SU, et al. Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma. Clin Translational Med. 2022;12(7):e934. https:\/\/doi.org\/10.1002\/ctm2.934.","journal-title":"Clin Translational Med"},{"issue":"10","key":"5146_CR84","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/ctm2.70010","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Lazaridou M, Korda\u00df T, et al. Unconventional microRNA role: Enhancing the human leukocyte antigen class I antigen processing pathway via interacting with a silencer. Clin Translational Med. 2024;14(10):e70010. https:\/\/doi.org\/10.1002\/ctm2.70010.","journal-title":"Clin Translational Med"},{"issue":"13","key":"5146_CR85","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/cells12131673","volume":"12","author":"X Chen","year":"2023","unstructured":"Chen X, Li Y, Xia H, Chen YH. Monocytes in Tumorigenesis and Tumor Immunotherapy. Cells. 2023;12(13):1673. https:\/\/doi.org\/10.3390\/cells12131673.","journal-title":"Cells"},{"issue":"4","key":"5146_CR86","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/cells11040697","volume":"11","author":"MW Ko","year":"2022","unstructured":"Ko MW, Kaur K, Safaei T, et al. Defective Patient NK Function Is Reversed by AJ2 Probiotic Bacteria or Addition of Allogeneic Healthy Monocytes. Cells. 2022;11(4):697. https:\/\/doi.org\/10.3390\/cells11040697.","journal-title":"Cells"},{"issue":"6","key":"5146_CR87","doi-asserted-by":"publisher","first-page":"e202000935","DOI":"10.26508\/lsa.202000935","volume":"4","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Steele NG, Carpenter ES, et al. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Life Sci Alliance. 2021;4(6):e202000935. https:\/\/doi.org\/10.26508\/lsa.202000935.","journal-title":"Life Sci Alliance"},{"issue":"11","key":"5146_CR88","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630\u20137. https:\/\/doi.org\/10.1038\/s41416-020-0802-1.","journal-title":"Br J Cancer"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05146-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:03:10Z","timestamp":1787936590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5146"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05146-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human buffy coats from healthy donors were obtained from the Blood Bank of Heidelberg University Hospital as anonymized surplus material. According to institutional and national regulations, the use of fully anonymized donor material for research purposes does not require additional ethical approval. All procedures were conducted in accordance with relevant guidelines and regulations. No animal experiments were performed in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"466"}}